Sermorelin vs tesamorelin: two routes to the same receptor, two very different approval histories

You read about sermorelin in one anti-aging clinic’s brochure. You read about tesamorelin in another. Same pituitary lever, both times. Same upstream story about growth hormone, both times. Two different molecules, two different prices, and almost no clinic explains why a buyer should care about the difference.

The difference is paperwork. Sermorelin once had two FDA approvals and lost them. Tesamorelin still has one. Neither approval was for what either compound is being sold for now. That is the entire shape of the comparison, and it changes nearly everything about how each one is bought, dispensed, and described.

Same receptor, different files. Let’s lay the two side-by-side and look at what each is actually carrying.

Same lever on the pituitary

Both compounds are growth-hormone-releasing-hormone agonists. They bind the same receptor on the same cells in the anterior pituitary and produce the same downstream signal — endogenous pulsatile GH release, IGF-1 elevation, the rest of the GHRH cascade.

Sermorelin is the first 29 amino acids of native human GHRH (1-44). Just the active-binding fragment, no chemical decoration. Half-life is short — minutes, not hours — because the body clears GHRH fragments quickly. Nightly subcutaneous dosing exists for that reason. Vittone and colleagues in 1997 (Metabolism) tested single nightly injections of strict GHRH (1-29) in healthy elderly men. The hormone-axis numbers moved.

Tesamorelin is full GHRH (1-44) with a trans-3-hexenoyl group attached at the N-terminus. The hexenoyl modification extends plasma half-life and blocks the enzyme that would otherwise clip the molecule apart. That single chemical change is what makes once-daily dosing clinically workable and what made an FDA drug application possible.

Same receptor. Same downstream signal. Different chemistry, different half-life, and as it turns out, different regulatory destinies.

A footnote that keeps getting dropped

Before the spec sheet, a detail that gets ironed out in the marketing and matters more than it should.

The 1990s sermorelin literature most often cited as the older-adult evidence base — Khorram and colleagues at the Yen lab — used a stabilised analog called [Nle27]GHRH (1-29), with a norleucine substitution at position 27. Which version is this is the question to keep in mind. The Nle27 analog is not strict sermorelin. It is a stabilised cousin, made to last longer in plasma than the unmodified fragment. The 1997 Khorram, Laughlin and Yen paper in the Journal of Clinical Endocrinology and Metabolism is on that analog, and the 1997 Khorram and colleagues paper in the same journal on aging-men-and-women immune markers is on the same analog. The clean statement when citing either is a stabilised sermorelin analog, not sermorelin itself.

The other footnote belongs to the cognition trial that the longevity case for sermorelin is most often built on. Baker and colleagues in 2012 (Archives of Neurology) is a real randomised, double-blind, placebo-controlled trial in 152 older adults — 66 with mild cognitive impairment, 86 cognitively healthy — across 20 weeks of nightly injection. Cognition moved at P equals 0.03. The trial is real. The compound injected was tesamorelin, not sermorelin. The same paper is regularly mis-attributed to sermorelin in anti-aging marketing copy. The honest citation is tesamorelin.

Those two footnotes — Nle27 versus strict sermorelin, and Baker 2012 as tesamorelin — pull the human file on the sermorelin side thinner than the brochures imply. They also explain why the clearest GHRH-cognition signal in print belongs to tesamorelin, not the molecule longevity clinics call sermorelin.

The spec sheet

Pull the basic structural and regulatory facts into one frame, because the marketing flattens these into two GHRH peptides when they are not.

Two things to take from the spec sheet. The mechanism column is genuinely identical — both molecules are pulling the same upstream lever on the pituitary. And the FDA column is genuinely opposite. One molecule had two approvals and lost both for business reasons. The other has one, and it is still on the market in a population almost no buyer belongs to.

What the sermorelin file actually contains

The honest read on sermorelin’s human evidence is that the published record in healthy adults is small, old, and partly attached to a sibling molecule.

In strict sermorelin — GHRH (1-29) with no modification — the foundational older-adult paper is Vittone and colleagues in 1997, in Metabolism, on single nightly injections in healthy elderly men. GH and IGF-1 moved in the expected direction. Sample sizes were small. The endpoints were biomarkers — pulse-integrated GH, serum IGF-1 — not body composition over a year or any functional measure.

The longer-term older-adult work is the 1997 Khorram, Laughlin and Yen paper in JCEM — the one already linked above on the Nle27 analog. Endocrine and metabolic effects moved in the expected direction over a sustained dosing period. Sample sizes were small. The molecule was the stabilised Nle27 analog, not strict sermorelin.

That is the older-adult sermorelin file. Two papers from the same lab, in the same year, in older healthy adults, on biomarkers. The single most-cited cognition trial that gets pulled toward this file — Baker 2012 in Archives of Neurology — used tesamorelin instead, with a follow-up biomarker analysis by Winston and colleagues in 2018 showing some synaptic-protein signal but no shift in amyloid or phosphorylated tau.

What the file does not contain: a strict-sermorelin controlled trial in healthy adults under 60 with hard outcomes. Not body composition, not functional fitness, not sleep with validated instruments, not cognition. The mechanism is plausible. The clinical evidence in the population doing the buying is largely extrapolated.

What the tesamorelin file actually contains

Tesamorelin has the GHRH-class file that includes a registered, completed Phase III trial in a real disease indication.

The pivotal trial is Falutz and colleagues in 2007, in the New England Journal of Medicine. 412 HIV-infected adults with abdominal-fat accumulation, 26 weeks, daily subcutaneous tesamorelin or placebo at the study dose. Visceral adipose tissue on CT fell 15.2 percent on tesamorelin and rose 5.0 percent on placebo. Triglycerides dropped. The total-to-HDL cholesterol ratio improved. That is the trial that got tesamorelin to NDA 022505 and Egrifta to market in 2010.

The single non-HIV randomised trial is Makimura and colleagues in 2012, in the Journal of Clinical Endocrinology and Metabolism. 60 abdominally obese non-HIV adults with reduced GH secretion, 12 months, tesamorelin or placebo. Visceral adipose tissue fell selectively on tesamorelin. Triglycerides, C-reactive protein, and carotid intima-media thickness improved without aggravating glucose tolerance. Small. Single-centre. One trial. Real placebo arm.

The cognition signal is Baker 2012 in Archives of Neurology — 152 older adults across 20 weeks, intent-to-treat analysis showing a favourable effect on cognition at P equals 0.03, with the modest synaptic-marker follow-up from Winston 2018. The intervention was tesamorelin. It is the strongest GHRH-class cognition result in the published human record, and it has not been replicated.

What the tesamorelin file does not contain: a trial in healthy adults without HIV lipodystrophy and without reduced GH secretion. Not body composition, not longevity-relevant outcomes, not the buyer’s population. The Phase III is in a narrow patient group by design. The Makimura paper widens the window only to non-HIV adults whose GH was already low. The off-label longevity case for tesamorelin in a healthy 45-year-old man is exactly that — off-label, on the strength of mechanism, not on a trial that asked the question.

The human file, side-by-side

This is the part the brochures almost never lay out cleanly.

Read those two columns honestly. On strict sermorelin, the human file in healthy adults is two small biomarker papers from the same lab in 1997 — one of them on a stabilised analog. On tesamorelin, the human file is a real Phase III in one disease population, a small non-HIV RCT, and a single positive cognition trial in older adults — none replicated outside the original groups.

So the GHRH-receptor agonist with the deeper published human evidence is tesamorelin, on every column where the comparison is even possible. Sermorelin’s case in the buyer’s population is largely extrapolated from older biomarker work plus the cognition trial belonging to tesamorelin. That is not the order in which the marketing usually presents it.

The off-label reality on both sides

Both compounds are sold to a population the FDA has never reviewed them in.

Sermorelin’s approved use was for diagnosing GH-axis defects (NDA 019863) and treating pediatric idiopathic GH deficiency (NDA 020443). Geref was withdrawn from the US market in 2008 for commercial reasons — Serono’s stated rationale — and the approvals were formally rescinded by the FDA on June 18, 2009, with the agency confirming the withdrawal was not for safety or efficacy. The active ingredient stayed available through compounding pharmacies under Section 503A. Compounded sermorelin today is prescribed off-label, mostly to healthy adults whose GH is age-lower but not clinically deficient — the population the original Geref clinical evidence did not study.

Tesamorelin’s approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. That is the population Falutz 2007 enrolled. Off-label prescribing in non-HIV adults is legal under standard US off-label prescribing rules. It is also a different population from the trial that earned the approval. And because tesamorelin’s active moiety is the active ingredient of an approved drug (Egrifta WR), the compounding picture is genuinely tighter than for sermorelin. Compounding pharmacies are barred under the FD&C Act from making substances that are essentially copies of commercially available approved drugs. Compounded tesamorelin has drawn FDA enforcement and continues to occupy a legally complicated position.

So the off-label posture is genuinely different between the two. With sermorelin, there is no approved commercial product to bump up against — the compounding lane is open because the drug-application lane is empty. With tesamorelin, there is an active commercial product on the market, and the compounding lane is closed for that reason. The same active ingredient that gives tesamorelin its evidence advantage also closes off the supply route that sermorelin’s evidence-thin status leaves open.

That is the trade nobody quite says out loud. The molecule with more evidence is harder to obtain through compounding. The molecule with less evidence is easier to obtain through compounding. The market-clearing price reflects that, and so does the prescription pad in most anti-aging clinics.

Where regulators stand on both, this July

Neither sermorelin nor tesamorelin is on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee docket per the April 2026 Federal Register notice. The notice names seven substances across the two-day session — BPC-157, KPV, TB-500, and MOTs-C on July 23, then Emideltide (DSIP), Semax, and Epitalon on July 24. Sermorelin and tesamorelin are absent from both days.

That absence means different things on each side.

For sermorelin, absence from the PCAC docket means the compound runs under the pre-existing pharmaceutical and compounding framework that has been in place since the Geref withdrawals. The PCAC review can change a lot of things about peptide compounding in July, but the lane sermorelin sits in is not the lane being reviewed. Compounded sermorelin’s availability does not turn on the July vote.

For tesamorelin, absence from the PCAC docket means something nearly opposite. Tesamorelin’s active moiety is already an approved drug, so it cannot be on a docket whose purpose is to evaluate whether unapproved bulk substances should be allowed under Section 503A compounding. The compound is regulated under the drug-approval framework, period. The compounding restrictions tied to its approved status are not being re-evaluated by PCAC at all.

WADA status is the clean line on both. The 2026 Prohibited List S2 — peptide hormones, growth factors, and related substances and mimetics — explicitly covers growth-hormone-releasing factors. Both sermorelin and tesamorelin are GHRFs by class. Both are prohibited at all times, in and out of competition, for athletes subject to WADA testing. Domestic legality and competition eligibility are separate questions, and they stay separate after July.

What would actually change the comparison

If you wanted the comparison to land on something firmer than same receptor, different paperwork, here is the short list of evidence neither side currently has.

For strict sermorelin, the missing piece is a controlled trial in healthy adults under 60 with outcomes the marketing actually promises. Not GH pulses. Not IGF-1 at four weeks. Body composition over a year, functional fitness, validated sleep instruments, cognition independent of any baseline impairment. Khorram 1997 measured the right axis. It measured it in 19 people over 16 weeks on a stabilised analog. Three decades later, that trial has not been re-run in a meaningful population.

For tesamorelin, the missing piece is the non-HIV, non-reduced-GH RCT — a controlled study in healthy adults whose growth hormone is age-lower but not clinically low. Makimura 2012 came close, in 60 subjects, in a population with reduced GH secretion. A trial in the actual buyer population — healthy adults pursuing longevity outcomes — has not been registered.

For the GHRH-class cognition signal, the missing piece is replication of Baker 2012 outside its original group, with the original molecule (tesamorelin), in a population without baseline cognitive impairment, with the same primary endpoint. A single trial is not the same as a settled finding, even when its P value is 0.03.

For long-term safety, neither compound has a published controlled exposure beyond months in the populations buying them. People prescribed either peptide for off-label longevity use often stay on for years. That dataset is not in print.

So which one, if you’re already deciding

Two questions live inside this one. They have different answers, and the answers run in opposite directions.

If you isolate the question to which GHRH-receptor agonist has the deeper published human evidence, it is tesamorelin. A real Phase III in a real disease indication. A small non-HIV RCT. A single positive cognition trial. The catch is that none of those studies enrolled the population doing most of the buying, and the molecule’s active-drug status puts the compounded supply route under enforcement pressure that sermorelin does not face.

If you isolate the question to which GHRH-receptor agonist is easier to obtain through legitimate compounding right now, it is sermorelin. The Geref withdrawal in 2009 was for commercial reasons rather than safety, and the active ingredient has remained available through Section 503A compounding. The catch is that the published human evidence for strict sermorelin in healthy adults is two 1997 biomarker papers from the same lab — and the cognition trial most often cited as the case for it belongs to tesamorelin.

Same receptor. Same downstream signal. One peptide is the approved drug for a population most readers do not belong to, with a supply route closed for that very reason. The other peptide is a compounded grey-market product whose own FDA approval was for uses almost nobody buys it for, with a supply route open for that very reason. The reason somebody is prescribed one versus the other is rarely a clean read on the evidence — it is usually a read on which compounding pathway the clinic prefers. Different approval histories, identical mechanism. That is the part the brochures keep flattening.

Different approval histories, one prescription path

The GHRH-class story is the part of the longevity menu where the compounding question and the drug-approval question both matter, in opposite directions, on the same prescription pad. Sermorelin’s compounded path is open because its drug-application lane is empty — Geref was withdrawn in 2009 for commercial reasons, leaving the active ingredient available through Section 503A. Tesamorelin’s compounded path is restricted because its drug-application lane is occupied — Egrifta WR is on market, so the FD&C Act constrains compounding of the same active moiety. Neither situation looks like the other from a brochure, and neither looks like the situation for the PCAC peptides being reviewed this July.

Wolverine Health is being built so the supervising physician can read each pathway honestly. Physician-supervised peptide protocols, US-licensed compounding pharmacies, every batch third-party tested. For sermorelin, the prescribing question is who actually benefits from a GHRH agonist whose strict-molecule human evidence in healthy adults is two papers from 1997 — both on the Nle27 analog, not strict sermorelin. For tesamorelin, the prescribing question is whether the off-label longevity case justifies a compounding posture the FDA actively scrutinises, given that the trial that earned the approval enrolled HIV lipodystrophy patients and the buyer almost never is one. Two different decisions on the same prescription pad, made by a doctor who actually reads the file.

That is the landscape we are designing the protocol around. For these two molecules in particular — which patient profile fits each pathway, which indications a supervising physician will prescribe for, and whether a given buyer should be on sermorelin, on tesamorelin, or on neither — the honest answer is rarely what the brochure implies. We will say so plainly when the service opens. Join the waitlist if you want a heads-up the moment that version is available.